EP1305021A4 - RAPID EXPANSION COMPOSITION FOR GASTRIC RETENTION AND REGULATED RELEASE OF THERAPEUTIC AGENTS, AND DOSAGE FORMS COMPRISING THE SAME - Google Patents

RAPID EXPANSION COMPOSITION FOR GASTRIC RETENTION AND REGULATED RELEASE OF THERAPEUTIC AGENTS, AND DOSAGE FORMS COMPRISING THE SAME

Info

Publication number
EP1305021A4
EP1305021A4 EP01946709A EP01946709A EP1305021A4 EP 1305021 A4 EP1305021 A4 EP 1305021A4 EP 01946709 A EP01946709 A EP 01946709A EP 01946709 A EP01946709 A EP 01946709A EP 1305021 A4 EP1305021 A4 EP 1305021A4
Authority
EP
European Patent Office
Prior art keywords
composition
dosage forms
therapeutic agents
controlled release
forms including
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01946709A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1305021A1 (en
Inventor
Moshe Fleshner-Barak
E Itzhak Lerner
Vered Rosenberger
Mazal Dahan
Yisrael Imakov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP1305021A1 publication Critical patent/EP1305021A1/en
Publication of EP1305021A4 publication Critical patent/EP1305021A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Manufacturing & Machinery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
EP01946709A 2000-06-23 2001-06-22 RAPID EXPANSION COMPOSITION FOR GASTRIC RETENTION AND REGULATED RELEASE OF THERAPEUTIC AGENTS, AND DOSAGE FORMS COMPRISING THE SAME Withdrawn EP1305021A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21383200P 2000-06-23 2000-06-23
US213832P 2000-06-23
US21711000P 2000-07-10 2000-07-10
US217110P 2000-07-10
US22321200P 2000-08-04 2000-08-04
US223212P 2000-08-04
PCT/US2001/020134 WO2002000213A1 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Publications (2)

Publication Number Publication Date
EP1305021A1 EP1305021A1 (en) 2003-05-02
EP1305021A4 true EP1305021A4 (en) 2009-09-23

Family

ID=27395915

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01946709A Withdrawn EP1305021A4 (en) 2000-06-23 2001-06-22 RAPID EXPANSION COMPOSITION FOR GASTRIC RETENTION AND REGULATED RELEASE OF THERAPEUTIC AGENTS, AND DOSAGE FORMS COMPRISING THE SAME

Country Status (11)

Country Link
EP (1) EP1305021A4 (enExample)
JP (1) JP2004501190A (enExample)
KR (1) KR20030013460A (enExample)
AU (2) AU6872201A (enExample)
CA (1) CA2412490A1 (enExample)
CZ (1) CZ2003199A3 (enExample)
EA (1) EA200300046A1 (enExample)
HU (1) HUP0301465A3 (enExample)
IL (1) IL153497A0 (enExample)
MX (1) MXPA02012793A (enExample)
WO (1) WO2002000213A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
MXPA04001388A (es) * 2001-08-16 2004-05-27 Oregon State Dispositivo de retencion gastrica expandible.
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
DK1615632T3 (da) * 2003-04-17 2007-04-10 Jallal Messadek Flydende orale formularer for kontrolleret udskillelse af betain
US20050113452A1 (en) * 2003-10-20 2005-05-26 Moshe Flashner-Barak Composition and dosage form for sustained effect of levodopa
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
EP2242489A1 (en) 2005-02-15 2010-10-27 Jallal Messadek Combination therapeutic compositions and method of use
CN101180073A (zh) 2005-04-27 2008-05-14 贾拉尔·梅萨德克 胰岛素组合
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
CN101636145B (zh) * 2006-05-31 2014-04-23 雅培产品有限公司 长期24小时经肠给予左旋多巴/卡比多巴
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
PE20080669A1 (es) * 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
WO2008039186A2 (en) * 2006-09-26 2008-04-03 Plensat, Llc Method and system for treatment of eating disorders
CA2673485A1 (en) 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
DE102007026037A1 (de) 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
WO2009017716A2 (en) * 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
US9320738B2 (en) 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
CN102202656A (zh) * 2008-08-15 2011-09-28 蒂宝制药公司 治疗和预防cns障碍的胃滞留药用组合物
CA2742680C (en) * 2008-11-07 2013-12-31 Samyang Corporation Pharmaceutical compositions for release control of methylphenidate
EP2661262B1 (en) * 2011-01-06 2017-11-15 Mahmut Bilgic Improved bisphosphonate formulations
CN103385871B (zh) * 2012-05-07 2017-06-23 新疆医科大学 复方左旋多巴微囊漂浮片
EP2858604B1 (en) 2012-06-07 2024-02-21 Epitomee Medical Ltd Expanded device
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
JP6204141B2 (ja) * 2013-04-22 2017-09-27 テイカ製薬株式会社 口腔内速崩壊性固形製剤用組成物
US10994013B2 (en) 2013-04-24 2021-05-04 Temple University—Of the Commonwealth System of Higher Education Solid dosage form containing arabinogalactan
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CA2926082C (en) 2013-10-07 2022-06-14 Impax Laboratories, Inc. Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
ES2926480T3 (es) 2013-12-05 2022-10-26 Epitomee Medical Ltd Dispositivos y sistemas retentivos para la liberación in situ de principios activos farmacéuticos
RS66154B1 (sr) * 2015-02-27 2024-12-31 Cingulate Therapeutics LLC Formulacije stimulansa sa tropulsnim oslobađanjem
JP6823539B2 (ja) * 2017-05-26 2021-02-03 株式会社ファンケル 胃内滞留性錠剤
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
CN110996922A (zh) * 2017-06-16 2020-04-10 卡希夫生物科学有限责任公司 用于持续药物递送的胃滞留剂型
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
WO2019246145A1 (en) 2018-06-18 2019-12-26 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
CA3065695C (en) 2018-06-27 2021-06-01 Kashiv Biosciences, Llc Self-regulating osmotic gastroretentive drug delivery systems
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤
EP3968980A1 (en) 2019-05-14 2022-03-23 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US20220241222A1 (en) * 2019-06-26 2022-08-04 Celista Pharmaceuticals Llc Atomoxetine hydrochloride extended release compositions and methods of use
WO2021176360A1 (en) * 2020-03-02 2021-09-10 Craft Health Pte Ltd Oral dosage forms for extended drug release
WO2022140448A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11571402B2 (en) * 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
EP0795324A2 (en) * 1996-02-19 1997-09-17 Jagotec Ag A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
WO1999004764A1 (en) * 1997-07-23 1999-02-04 Perio Products Ltd. Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
EP0795324A2 (en) * 1996-02-19 1997-09-17 Jagotec Ag A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
WO1999004764A1 (en) * 1997-07-23 1999-02-04 Perio Products Ltd. Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0200213A1 *

Also Published As

Publication number Publication date
AU2001268722B8 (en) 2005-09-29
AU6872201A (en) 2002-01-08
HUP0301465A3 (en) 2006-07-28
AU2001268722B2 (en) 2005-08-11
KR20030013460A (ko) 2003-02-14
HUP0301465A2 (hu) 2004-05-28
IL153497A0 (en) 2003-07-06
CA2412490A1 (en) 2002-01-03
EP1305021A1 (en) 2003-05-02
CZ2003199A3 (cs) 2003-12-17
EA200300046A1 (ru) 2003-10-30
MXPA02012793A (es) 2004-07-30
JP2004501190A (ja) 2004-01-15
WO2002000213A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
HUP0301465A3 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
AU8405201A (en) Contraception process and administration form for the same
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
MXPA03003895A (es) Formulaciones de hidrocodona de liberacion controlada.
HUP0301242A3 (en) Controlled release drug dosage form
AU2001253479A1 (en) Targeted therapeutic agent release devices and methods of making and using the same
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL153708A0 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
PL366216A1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU2002360717A1 (en) Controlled release dosage form having improved drug release properties
GB0002386D0 (en) Therapeutic composition
FI20000780L (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
MXPA03004303A (es) DERIVADOS SUSTITUIDOS DE ACIDO AMINO-FURAN-2-IL-ACETICO Y ACIDO AMINO-TIEN-2-IL-ACETICO Y SU USO PARA EL TRATAMIENTO DE MIGRAnA Y DOLOR.
AU2001232948A1 (en) Controlled release of drugs
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HUP0204417A3 (en) Oral ciprofloxacin-composition of controlled release
IL137275A0 (en) Pharmaceutical composition for the treatment of anal fissures
GB0030067D0 (en) Therapeutic agent
AU5565401A (en) Materials and methods for the treatment of depression
IL155819A0 (en) Methods of treatment comprising administration of substance p
PH12001001922B1 (en) Crystalline therapeutic agent.
IL135993A0 (en) Pharmaceutical composition for the treatment of fibrosis
AU2001272552A1 (en) Oxygen-enriched agent and the use thereof for therapeutic purposes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030121

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20090825

17Q First examination report despatched

Effective date: 20100816

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101228